MELBOURNE, Australia, 13th-15th October 2020: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, is set to demonstrate its revolutionary skin cancer detection technology at the General Practice Conference & Exhibition in Melbourne in October.
The General Practice Conference & Exhibition (GPCE) in Melbourne is Victoria’s leading CPD event for primary care and one of the most important CPD events on the general practice calendar. Hundreds of healthcare professionals will meet in Melbourne to update knowledge, earn CPD points and see the latest primary care innovations.
Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor team will showcase the DermaSensor device. This easy-to-use, handheld device uses world-first technology to complement the skills and experience clinicians use in decision making by providing accurate differentiation between malignant and benign skin lesions. A recent clinical study found that DermaSensor achieved a sensitivity of 100 percent for detecting melanoma and 94 percent for detecting nonmelanoma skin cancer.
“We are delighted to show how DermaSensor’s technology can help clinicians rapidly and effectively check for skin cancer,” explains Kevin. “The device uses optical spectroscopy and machine learning technology to assess a lesion in under 30 seconds,” he says.
The technology, which was pioneered at Boston University and University College London, uses Elastic Scattering Spectroscopy. The non-invasive technique uses light of varying wavelengths. A physician gently touches the non-invasive device tip to a selected mole and a spectral sensor records how dozens of wavelengths of light reflect off cells beneath the surface of the skin.
The company’s proprietary algorithm instantly analyses the reflected photons to provide a simple “Higher Risk” or “Lower Risk” output to support a physician’s referral decision. It complements the physician’s skill and experience by using the power of machine learning to support clinical evaluation.
DermaSensor has spent the past three years miniaturising its spectroscopy technology into an easy-to-use handheld device. Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and it allows medical practitioners to spend less time on lengthy procedures.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. The DermaSensor device is low-cost and easy-to-use. It enables healthcare providers and patients to receive fast and accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.